Elon Musk has publicly responded to recent allegations regarding his substance use while serving in a government role. A report raised concerns over Musk's consumption of drugs such as ketamine, ecstasy, and psychedelic mushrooms during his involvement in the so-called "department of government efficiency." This report highlighted the contradiction between his influential position and his alleged drug use.
Sources indicated that Musk's daily medication regimen included around 20 pills, including Adderall, raising questions about the impact on his professional responsibilities. Despite his own statement in early 2024 asserting that he used ketamine in small doses biweekly and maintained high productivity, insiders claim his usage was more frequent, resulting in health complications.
Musk's increasing role in the administration was accompanied by erratic behavior, including controversial public appearances and insults directed at cabinet members. These actions drew significant criticism and speculation about his judgment and fitness for government work.
It is important to note that ecstasy is classified as a Schedule I controlled substance with no accepted medical use, making its use federally prohibited, especially among government employees. Although Musk's status as a "special government employee" exempts him from certain restrictions, recreational use of substances like ketamine would contravene federal workplace policies.
Following Musk’s departure from his government role, debates have emerged about substance use and accountability in positions of power. Reports also indicated that despite strict drug policies at companies like SpaceX, Musk may have received advance notice of drug tests, casting doubt on their integrity.
During a farewell event, Musk dismissed the drug use allegations, criticizing the publication responsible and referencing its past controversies. When questioned by media about White House concerns over the matter, a senior official declined to comment directly, shifting focus to other policy issues.
The developments shed light on the complexities of managing personal conduct and public trust in high-profile government roles.
